Harvard Medical School
Harvard University
UCLA Medical Center Blood Bank
UCLA Tissue Typing Laboratory
UCLA Stem Cell Laboratory
UCLA Clinical Laboratory
UCLA/National Institute of Health COBLT Cord Blood Bank
City of Hope National Cancer Center
American Red Cross Blood Center
Ohio State University
Jonas Wang, Ph.D.
Chief Operation Officer
Jonas Wang joined StemCyte in 2009. Prior to joining StemCyte, he was a Partner of Sycamore Management Corporation in Princeton. Mr. Wang focuses on life sciences and biotechnology investments, and prior to joining Sycamore in 2001, he was Vice President of Research and Technology at Johnson & Johnson ("J&J") Consumer Products and a Corporate Director of J&J Drug Delivery Technology Resource Center, responsible for new product technology, patent strategy, competitive intelligence, and new measurement methodology for skin and hair care franchise. Prior to joining J&J, Mr. Wang was an Associate Director of Basic Pharmaceutics, the Pharmaceutical Research Institute of Bristol-Myers Squibb Co. He has over 30 years of experience in pharmaceutical R&D management and business development. He was also a member of J&J Consumer Product Worldwide Licensing and Acquisition Committee and was the key driver for several major acquisitions. He has published extensively in drug delivery technology and received several awards in his field, including the Johnson Medal, the highest technical achievement award at J&J, for one of his inventions, anti-wrinkle cream. Mr Wang received the Distinguished Alumni awards from the National Defense Medical Center in Taiwan, Republic of China, and also from the University of Iowa. During his career with J&J, he developed more than 10 core technologies, and filed more than 30 business-related patents. He received a Ph.D. in Physical Pharmacy from University of Iowa and Pharmacy degree from National Defense Medical Center in Taiwan, Republic of China.
Calvin Cole
President, North America
Calvin Cole leads StemCyte’s North America initiatives and strategic business development across the organization with a focus on developing external staff. He is also responsible for leveraging the StemCyte Brand to help define the competitive advantages with Private Banking business. Before joining StemCyte, he was Vice President for Hoveround Power Wheelchairs. While there, he was responsible for product marketing, strategic planning, new product planning, business development and Government Relations. He has spent the last 15 years Lobbying Washington on issues for The Home Medical Equipment industry. He was educated at Richland College and served in the United States Army where he was Honorably Discharged in 1984.
Tom Flaherty
Vice President, Finance
Tom Flaherty has 20 years’ experience in accounting, finance & entrepreneurial management. Before joining StemCyte in 2008, he was Corporate Controller of VPIsystems, Inc, a global venture backed software company, where he supported over $25M of Equity and Debt financing and managed the global finance teams. Previously he was founder of 2 start-up companies, Director of Accounting of Centennial Communications, a publicly traded wireless communications company and Audit Manager at Ernst & Young, a "Big 4" public accounting firm. He is a Certified Public Accountant and holds a B.S. degree in Accounting from Montclair State University.
Charles Lu
President, StemCyte Taiwan
Charles Lu has more than 16 years of experience in pharmaceutical and medical devices business development. Prior to joining StemCyte in 2004, he was the Chairman and General Manager of You An, a drugstore group in Taiwan, which he developed from three stores to 50 stores within three years. Previously, Mr. Lu was a senior marketing executive with Johnson & Johnson’s Janssen Pharmaceutical unit, developing marketing programs for important products including Nizoral, Resperidol, EPO, Cisapride and Itraconozole. He received a B.S. degree in Medical Technology from Chung Shan Medical University and an M.B.A. degree (Paris) from University of Hartford.
Tushar Dalal
President, StemCyte India Therapeutics
Tushar Dalal spent 5 years in the USA both completing his undergraduate and graduate studies at North Carolina State University and gaining work experience in Los Angeles before returning to India to start his own business in the Specialty Chemical and Dyestuff Industry which he lead and grew into a successful enterprise. He is a highly respected member of the Business Community and is very well connected with the Political Establishment of the prominent and prosperous State of Gujarat where StemCyte India is located. He received his undergraduate education at Gujarat University and his graduate degree at North Carolina State University.
Prof. Wise Young, M.D., Ph.D.
Chief Science & Medical Advisor
Dr. Wise Young, Richard H. Shindell Distinguished Chair in Neuroscience and Founding Director, W.M. Keck Center for Collaborative Neuroscience at Rutgers, The State University of New Jersey, is one of the world’s most outstanding neuroscientists and a foremost leader in spinal cord injury research. With a B.A. from Reed College, a Ph.D. from University of Iowa, an M.D. from Stanford University and a Surgery Internship at New York University (NYU) and Bellevue Medical Center, he became Director of Neurosurgery Research at NYU. He was a part of the team which discovered and established high-dose methypredisolone (MP) as the first effective therapy for spinal cord injuries. The team also played a major role in Andy Blight’s signal work on 4-aminopyridine (4-AP) which shows significant promise for increasing nerve conductivity. His pioneering standardized rat spinal cord injury model is used worldwide for testing therapies. He was the founder and editor-in-chief of the Journal of Neurotrauma, organizer of National and International Neurotrauma Societies, member of the Advisory Committees for the NIH, the National Academy of Sciences, NICHD and many spinal cord injury organizations. He has appeared as a guest on "20/20", "48 Hours", "Today", "Eye to Eye", Fox News and CNN. His work has been featured in a Life magazine special edition, in USA Today, and in numerous news, talk and print presentations worldwide. His honors include: NIH Jacob Javits Neuroscience Award (1985-1992), Wakeman Award (1991), Tall Texan of the Year Award (1997), "Cure" Award (1998), Trustees Award for Excellence in Research (2001), 2002 Asian American Achievement Award, Douglass Medal for work with the advancement of young women in the sciences (2003), and Elizabeth M. Boggs Award for service to the disability community (2004). In August 2001, TIME Magazine named Dr. Young as 'America’s Best' in the field of spinal cord injury research. In 2005 he was the first researcher elected to the Spinal Cord Injury Hall of Fame. In 2006, Dr. Young received The Hope Award – A Salute to Research Innovation, the New Jersey Educator of the Year Award, and the Caring Heart Award. When the Richard H. Shindell Chair in Neuroscience was established at Rutgers University in 2006, Dr. Young was named as the first person to hold that chair. In 2007 the Motolinsky Foundation named Wise Young as the recipient of their Distinguished Citizen Award.
Prof. Shinn-Zong Lin, M.D., Ph.D.
Chief Medical Officer, StemCyte Taiwan
Dr. Shinn-Zong (John) Lin is a Professor of Neurosurgery and Vice Superintendent of the Center of Neuropsychiatry at China Medical University Hospital in Taiwan. With an M.D. from National Defense Medical Center in Taipei, a Ph.D. in Physiology and Biophysics from State University of New York at Stony Brook and a Master’s degree in Medical Management from Tulane University, he has served as a Professor of Neurosurgery at the National Defense Medical Center, Chairman of the Department of Neurosurgery at Tri-Service General Hospital, and a Professor of Neurosurgery and Chairman of NeuroMedical Scientific Center at Tzu-Chi General Hospital. He is the inventor of many patented treatment technology for Brain Damage patients including the patentable technology entitled, "Treatment of Brain Damage using umbilical Cord Blood Cells". His background also includes: Membership of Editorial Boards Tzu-Chi Nursing Journal, Tzu-Chi Medical Journal, Formosan Journal of Surgery, Acta Neurologica Taiwanica, Surgical Neurology and Taiwan Neuroscience Alliance, Presidency of the International Neural Transplantation and Repair Meeting, Membership of 23 Professional Societies, 25 Distinguished Honors and Awards, 41 Research Programs, 3 Patents, 161 Publications in refereed journals, 25 Books and 178 Conference Papers and Invited Lectures. He is a highly accomplished neurosurgeon and applied neuroscientist for innovative therapies for stroke and neurodegenerative diseases.
Mark Maciejewski
Member, BOD
Mark Maciejewski is the Senior Vice President of International Investment, at National Technology Enterprise Company, which is a Division of the Kuwait Investment Authority based in Kuwait City. Prior to this, he was Founder, Director, President, and Chief Executive Officer of Symphony Medical, Inc. He also held the position of Managing Director, Healthcare, for Tyco Ventures, a corporate sponsored venture capital firm of Tyco International Ltd., and, previously, he was the founder of Ascent Private Equity, a medical technology focused venture capital firm located in New York City. He has 21 years experience in the medical technology industry, including launching a variety of medical device start-ups such as Angioguard (acquired by Johnson & Johnson), Devax, Inc., American Medical Systems, InStent, Palamar Medical and Angiosonics. His medical technology expertise is enhanced by his experience in worldwide sales and marketing management and product and business development. He received his B.S. from the University of Dayton, and an M.B.A. from St. Thomas University in St. Paul.
David G. Wang M.D., Ph.D.
Member, BOD
Dr. David Wang of WI Harper has more than 15 years of life sciences and senior executive experience in pharmaceutical development, molecular diagnostics, medical device, and diagnostic imaging. He is currently responsible for investment activities in life sciences and healthcare at WI Harper. Most recently, he served as Head of Business Development in Molecular Medicine at Siemens Medical Solutions, where he directed corporate strategy, new businesses, and investments in diagnostics and molecular imaging. Previously, he was co-founder and Executive Vice President at First Genetic Trust, a personalized medicine company in the U.S. During his tenure at Bristol-Myers Squibb, he was the Chairman of The SNP Consortium Management Committee where he was responsible for strategy and management of the consortium. The SNP Consortium is the first group of its kind formed by pharmaceutical and technology industries as well as academia and charities to support the development and adoption of personalized medicine. He published numerous articles on genetics and personalized medicine when he was at Whitehead/MIT. His 1998 article in Science was the most cited paper in 1999, and was selected by Science along with others as one of the nine discoveries that transform our ideas about the natural world and also offer potential benefits to society. He received his M.D. from Peking University Medical School. He earned his doctorate in Developmental Biology from California Institute of Technology.
George J. Lee, Ph.D.
Member, BOD
George J. Lee is a general partner and co-founder of AmKey Ventures, LLC, a venture management company specializing in investments in the biotech and pharmaceutical fields. He has extensive experience in the pharmaceutical industry, having worked in a major pharmaceutical company (Syntex) for 13 years and early stage biomedical companies (Sonus and Shaman Pharmaceuticals) for 7 years. He is an internationally known pioneer in the field of steroid hormones research. His HPLC-RIA method has been recognized as the most accurate and sensitive method for the determination of trace amounts of steroid hormones in the complex biological matrices. He has in depth experience in analytical methods development and validation for New Drug Application (NDA) as well as various applications to the Food & Drug Administration. He is a co-founder of PHARMout Laboratories, Inc., which is a contract research organization specializing in analytical research. PHARMout Laboratories has received excellent results from several FDA inspections. PHARMout Labs. has achieved an over 30% net profit margin and consequently provided good return to its shareholders. He earned his Ph.D. degree in chemistry from the State University of New York at Buffalo and a B.S. degree in agricultural chemistry from National Taiwan University, Taiwan.
Barry Ressler
Member, BOD
Barry Ressler is the Founder, Chief Executive Officer and Chairman of the Board of Triton Thalassic Technologies, Inc. (T3I), a company engaged in the non-chemical pathogen inactivation of blood products, photo-activation of therapeutic compounds and the treatment and control of micro-organism contaminated fluids for the industrial, food packaging, healthcare and pharmaceutical industries. He is also the Chairman of the Board of Directors of EP Therapeutics, Inc., an early stage bio-pharmaceutical company engaged in the development of a revolutionary new class of therapeutics as safer, alternative treatments for human cancers by eliminating the need for chemotherapy or radiation treatment protocols and the President of STAR Associates, Inc., a company engaged in the consultation, strategic planning and project funding of early stage industrial process and therapeutic/diagnostic technologies. He has formerly served as Chief Executive Officer and Chairman of the Board of Universal Voltronics Corporation (UVC), a public company (NASDAQ and AMEX) that developed high-voltage Pulse Power products for scientific research, defense, alternative energy sources, medical diagnostics/therapies and for industrial applications; UVC became a public subsidiary of Thermo Electron Corp, now Thermo Fisher Scientific. Subsequently, he became a member of the Board of Directors and Chairman of the of Corporate Governance Committee of JMAR Technologies Inc., (NASDAQ JMAR), the originator of Collimated Plasma Lithography and products for the public and private sectors based on its proprietary "Britelight(TM)" laser light source and homeland security for the detection of explosives, toxic gases (nerve and blister agents), and pollutants, and then he served as a member of the Sciences Business and Technology Advisory Board of Nauticos Corp., involved in the development of advanced side scan sonar, ROV and research protocols used in the discovery of historic and contemporary sunken vessels. He has also served on the scientific advisory board of the University of Connecticut Biotechnology center. He is the inventor of 4 patents in the field of monochromatic UV sterilization of industrial fluids, blood products, injectables, ophthalmic healthcare packaged products and patent pending IV technology and food process applications. He is an Alumnus of Pratt Institute (Engineering Science) and LI University (Business Administration).
James B. McCarthy
Member, BOD
James McCarthy is the Chairman & Chief Executive Officer of Gemini Consulting Group, Inc., addressing legal, organizational and financial issues for clients and partners. Prior to forming Gemini Consulting Group, he was the Executive Vice President of a Chicago-based health care consulting company, Vice President and General Manager of a medical device manufacturing company in Chicago, and an Executive in the Medical Products Division of 3M Company. His 30 years of experience in the health care field has ranged from analysis, planning and management in developing hospitals, ambulatory surgery and diagnostic centers, implementing hospital and physician joint venture strategies, and organizing domestic and international medical supply and equipment arrangements. He is a member of the Board of Directors of Protein Polymer Technologies, Inc., and JMAR Technologies, Inc., both of California, and Sirigen Group Ltd., of London. He is also a member of the Board of Trustees of the University of San Diego, California. He received a B.A. from the University of Notre Dame, a J.D. from the Loyola University School of Law, and an M.B.A. from the Keller Graduate School of Management, Chicago. He is active as a member of the American Health Lawyers’ Association, National Advisory Council of the Keller Graduate School of Management, the British-American Business Council and the National Strategy Forum in Chicago.
Professor Lawrence D. Petz, M.D.
Chief Medical Officer, StemCyte International Cord Blood Center Emeritus Professor of Pathology and Laboratory Medicine Former Director of Transfusion Medicine, UCLA Medical Center Los Angeles, California
Dr. Petz joined StemCyte after serving as Director of Transfusion Medicine and Professor of Pathology & Laboratory Medicine at UCLA Medical Center. Prior to UCLA, Dr. Petz was Chairman of the Division of Medicine, Section Head of Hematology, and Director of the Department of Clinical and Experimental Immunology at the City of Hope National Medical Center. Dr. Petz is the author or editor of several well-known, authoritative textbooks, including the first bone marrow stem cell transplant textbook, Clinical Bone Marrow Transplantation (1983), all three editions of the widely used blood bank textbook, Clinical Practice of Transfusion Medicine, and the co-author of Immune Hemolytic Anemias, now in its second edition. As a pre-eminent authority in transfusion medicine and transplantation, Dr. Petz has authored and edited hundreds of publications, book chapters, and reviews, and has published in New England Journal of Medicine, JAMA, Lancet, Annals of Internal Medicine, Transfusion Medicine, Transfusion, Transplantation, Bone Marrow Transplant, Journal of Clinical Investigation, Postgraduate Medicine, Transfusion Medicine, Medicine, Journal of Immunology, Blood, British Journal of Hematology, to name just a few. Dr. Petz is a diplomate in internal medicine and subspecialty board diplomate in hematology. He has chaired or served on over twenty transfusion medicine and hematology committees, and has received some of the highest honors in transfusion medicine, including the Emily Cooley Award, the and Morten Grove-Rasmussen Memorial Award and the Tibor Greenwalt Memorial Award and Lectureship from the American Association of Blood Banks (AABB); the Transfusion Medicine Academic Award from National Heart, Lung, and Blood Institute; and the Owen Thomas Award from the California Blood Bank Society. Dr. Petz chairs StemCyte's prestigious Medical Advisory Board.
Ram Bhat, Ph.D.
Chief Scientific Officer
Dr. Ram Bhat joined StemCyte in late 2005 as the Chief Scientific Officer. His previous professional tenure included two years of teaching at the University of Maryland at College Park and nearly 30 years at Johnson & Johnson where his assignments ranged from Manager of Basic & Applied Research at Baby Products Company to Director of Research at Vistakon, Director of Technology Transfer in Japan, Corporate Director at Corporate Office of Science & Technology and Vice President & Executive Director at Vision Care. His career is also highlighted by a one year White House (Executive Branch) Fellowship at the Office of Science & Technology Policy during the Clinton Administration. Dr. Bhat’s educational background consists of B. S. degrees in Physics, Mathematics and Engineering from India, M. S. and Ph. D. degrees in Polymer Science (Physics) from N. C. State University, and a Post-Doctoral Fellowship at the National Bureau of Standards.
Kenneth J. Giacin, MBA, MS
Chairman & Chief Executive Officer
Ken Giacin joined StemCyte in 2003, bringing world-class leadership to guide the company's growth through new investments and technological affiliations. Prior to joining StemCyte, he held positions as Senior Vice President of Independence Technology at Johnson & Johnson, Corporate Vice President at Church & Dwight/Arm & Hammer, and was Vice President of Johnson & Johnson Baby Products Co. Mr. Giacin holds both an M.B.A. and an M.S. degree from Rutgers University. Prior to his career in business, he served as a carrier pilot and officer in the U.S. Navy.
Robert Chow, M.D.
Vice Chairman & Founder Global Medical Director, StemCyte, Inc.
Dr. Chow is the Founder of StemCyte and successfully raised several rounds of investment as its founding Chairman. He currently serves as StemCyte’s Vice-Chairman. A physician-scientist-entrepreneur, he founded three other companies. As an ex officio member of the Executive Committee and Cord Blood Committee of the National Marrow Donor Program, Dr. Chow serves or has served as the Chairman or Board Director for numerous companies. Inventor of StemCyte cord blood technologies, he has several patents pending or allowed. Dr. Chow earned his M. D. and A. M. at Harvard Medical School, followed by Residency and Fellowship in Laboratory Medicine at UCLA.
Charles Lu
Chief Executive Officer, StemCyte Taiwan
Mr. Lu has more than 13 years of experience in pharmaceutical business development and medical devices. Prior to joining StemCyte, Mr. Lu was the Chairman and General Manager of You An, a drugstore group in Taiwan, which he developed from three stores to 50 stores within three years. Previously, Mr. Lu was a senior marketing executive with Johnson & Johnson’s Janssen Pharmaceutical unit. Mr. Lu received his M.B.A. from the University of Hartford Business School in Paris.
